Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:03 AM
Ignite Modification Date:
2025-12-25 @ 2:03 AM
NCT ID:
NCT07163260
Eligibility Criteria:
Inclusion Criteria:
For Experienced/Senior Treating Physicians
* Experienced/senior haematologist treating haemophilia (adult or paediatric) or physician treating patients with haemophilia. (PWH), with greater than 5 years of experience.
* Able to communicate in English or country specific language.
* Agree/sign informed consent before data collection. For Patients Organisations
* Patient organisation supporting haemophilia.
* Expert having greater than 3 years of work experience with the patient organisation.
* Expert level understanding of haemophilia landscape and care pathway in the relevant country.
* Able to communicate in English or country specific language.
* Agree/sign informed consent before data collection. For Patients/Caregivers
1. Patients of all age groups, diagnosed with haemophilia A or haemophilia B (with or without inhibitors) for greater than 2 years.
2. For patients less than 18 years of age (\*less than 19 years for South Korea), their caregivers aged greater than or equal to 18 years (\*greater than or equal to19 years for South Korea) should sign the informed consent.
\*For South Korea, the adult age is 19 years.
3. Able to communicate in English or country specific language.
4. Agree/sign informed consent before data collection.
Exclusion Criteria:
* There is no explicit exclusion criterion in this study, thus any participants group who answers "no" to any of the inclusion criteria will be excluded from the study.
Sex:
ALL
Study:
NCT07163260
Study Brief:
Protocol Section:
NCT07163260